ELIQUIS® is an oral anticoagulant that offers a 12–24 hour post-surgery initiation window and BD dosing.1
The ELIQUIS® (apixaban 2.5mg tablets BD*) dosing regimen was specifically selected to increase VTE prevention without increasing bleeding risk vs. the OD regimen in patients undergoing total hip replacement (THR) and total knee replacement (TKR).2,3
ELIQUIS® 2.5 mg BD in all indicated patients for1:
The initial dose of ELIQUIS® should be taken 12–24 hours after surgery,1 which allows:
*Physicians may consider the potential benefits of earlier anticoagulation for VTE prophylaxis as well as the risks of post-surgical bleeding in deciding on the time of administration within this time window.
ƗProvided haemostasis has been established.
Adapted from reference 1
*There is limited clinical experience in elderly patients co-administered ELIQUIS® with acetylsalicylic acid. This combination should be used cautiously because of a potentially higher bleeding risk.
**ELIQUIS® alone or in combination with acetylsalicylic acid should be used with caution in patients with severe renal impairment (CrCl 15–29 ml/min) because of a potentially higher risk of bleeding. ELIQUIS® is not recommended for use in patients with CrCl <15 ml/min. or in patients undergoing dialysis